Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder ...

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Zydus Lifesciences said its U.S.-based biopharmaceutical arm, Sentynl Therapeutics Inc, announced that the U.S. Food and Drug Administration (FDA) has approved ZYCUBO (copper histidinate) for the ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

ZYCUBO is a subcutaneous injectable formulation of copper histidinate designed to restore copper homeostasis and maintain adequate copper levels in patients with Menkes disease.

Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...

Shares of Intellia Therapeutics NTLA have plunged 55.2% over the past three months.The steep decline follows a significant regulatory setback related to nexiguran ziclumeran (nex-z), NTLA’s lead ...

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...